Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: A prospective, real-life, observational study

Table 1 Baseline characteristics of the patients (n = 674): Univariate analysis

	Therapeutic education
	No (n = 304)	Yes (n = 370)	P
Socio-demography
Men	170/303 (56)	229/370 (62)	0.14
Age (yr)	44.1 ± 11.4	44.9 ± 11.4	0.16
Body mass index (kg/m2)	23.5 ± 4.1	24.1 ± 4.2	0.06
Employment status
Professional activity	190/303 (63)	220/370 (59)	0.59
Unemployed	48/303 (16)	69/370 (19)
Other	65/303 (22)	81/370 (22)
Educational level
Low	182/300 (61)	223/365 (61)	0.94
High	118/300 (39)	142/365 (39)
Origin of incomes
Paid employment	166/298 (56)	183/368 (50)	0.24
Unemployment incomes	48/298 (16)	60/368 (16)
Other	84/298 (28)	125/368 (34)
Debts
Difficult to manage	8/232 (4)	27/315 (9)	0.02
None or easily managed	224/232 (97)	288/315 (91)
Comorbidities
Past psychiatric history
Depression	67/303 (22)	113/370 (31)	0.01
Suicide attempt	23/302 (8)	29/368 (8)	0.81
Hospitalisation for mental disease	25/301 (8)	36/369 (10)	0.59
Psychiatric disorder	60/300 (20)	98/367 (27)	0.04
Chronic disease	64/298 (22)	89/366 (24)	0.41
Risk factors
Alcohol consumption > 20 g/d	10/70 (14)	24/100(24)	0.17
Tobacco consumption	167/299 (56)	187/366 (51)	0.24
Drug abuse
None	139/303 (46)	172/368 (47)	0.02
Former	158/303 (52)	174/368 (47)
Current	6/303 (2)	22/368 (6)
HCV infection
Source of HCV infection1
Transfusion	62/304 (20)	76/370 (21)	1.00
Injection or intranasal drug abuse	157/304 (52)	193/370 (52)	0.94
Other	86/304 (29)	100/370 (27)	0.86
Duration of HCV infection year)	20.4 ± 8.4	20.0 ± 8.9	0.85
Serum HCV-RNA
≤ 800 000 IU/mL or equivalent	121/193 (63)	162/265 (61)	0.77
> 800 000 IU/mL or equivalent	72/193 (37)	103/265 (39)
HCV genotype
2	85/304 (28)	117/370 (32)	0.31
3	219/304 (72)	253/370 (68)	0.31
Coinfection
Human immunodeficiency virus	12/303 (4)	14/369 (4)	1.00
Hepatitis B virus2	3/301 (1)	6/369 (2)	0.63
Metavir activity grade or equivalent
A0 or A1	119/226 (53)	131/272 (48)	0.32
A2 or A3	107/226 (47)	141/272 (52)
Metavir fibrosis stage or equivalent
F0 or F1	110/227 (49)	109/272 (40)	0.04
F2 or F3	82/227 (36)	129/272 (47)
F4	35/227 (15)	34/272 (13)
Knodell score	7.9 ± 3.0	8.4 ± 3.5	0.19
Previous anti-HCV treatment course
None	242/303 (80)	303/370 (82)	0.74
One or more	61/303 (20)	67/370 (18)

Data are expressed as mean ± SD, or proportions of patients.

¹One patient could have more than one presumed source of infection.

²Hepatitis B antigen positivity.